Anzeige
Meldung des Tages: BREAKING NEWS: Pacifica liefert hochgradige Treffer - Phase II trifft genau ins Ziel

Icecure Medical News

Aktie
WKN:  A1W1LG ISIN:  IL0011224156 US-Symbol:  ICCM Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Israel
0,3536 $
-0,0023 $
-0,65%
0,30117 € 21.04.26
Depot/Watchlist
Marktkapitalisierung *
34,19 Mio. €
Streubesitz
52,20%
KGV
-
Index-Zuordnung
-

Icecure Medical News

14.11.25 - PR Newswire
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
12.11.25 - PR Newswire
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 PR Newswire
10.11.25 - PR Newswire
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction PR Newswire
03.11.25 - PR Newswire
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-​Specific 5-year Survival PR Newswire
13.10.25 - PR Newswire
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances PR Newswire
09.10.25 - PR Newswire
IceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure Medical to Attend the 2025 Maxim Growth Summit PR Newswire
03.10.25 - PR Newswire
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in ...
03.10.25 - PR Newswire
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above PR Newswire
30.09.25 - PR Newswire
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-​Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies ...
22.09.25 - PR Newswire
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented PR Newswire
18.09.25 - PR Newswire
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
IceCure Granted Notice of Allowance for U.S. Patent for its Next-​Generation XSense™ Cryoprobes PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
15.09.25 - PR Newswire
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
IceCure Receives Regulatory Approval in Israel for its Next-​Generation XSense™ Cryoablation System for Breast Cancer and Other Indications PR Newswire
08.09.25 - PR Newswire
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® ...
04.09.25 - PR Newswire
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy PR Newswire
13.08.25 - PR Newswire
IceCure Reports Financial & Operational Results for the First Half of 2025
IceCure Reports Financial & Operational Results for the First Half of 2025 PR Newswire
06.08.25 - PR Newswire
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025 PR Newswire
29.07.25 - PR Newswire
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
IceCure Announces Expiration and Results of Approximately Two Times Over-​Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million PR Newswire
25.07.25 - PR Newswire
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation PR Newswire

Newssuche

Videos

newspaper
20.04.26 -1,87%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »